Supplementary

Table S1 The inclusion criteria and exclusion criteria for this multicenter, randomized controlled trial (20)

Variable	Indicator details
Inclusion criteria	Patients with the following conditions:
	a. Patients with PE or IVC or iliac, femoral, or popliteal vein thrombosis with one of the following conditions:
	(i) Contraindications of anticoagulation therapy, such as as recent bleeding, bleeding during anticoagulant therapy, or recurrent PE;
	(ii) PE coupled with LEDVT;
	(iii) Free-floating thrombi or a large number of thrombi in the iliac and femoral veins or IVC;
	(iv) Patients diagnosed with thrombophilia and repeated PE occurrence;
	(v) Patients with acute LEDVT intending to undergo thrombolysis or PMT;
	b. 15 mm ≤ IVC diameter ≤30 mm;
	c. Age 18 years or older (no restriction on gender);
	d. Voluntarily participation, signed informed consent form, and ability cooperate with the entirety of the test process.
Exclusion criteria	Patients with one or more of the following conditions:
	a. Infection present in the puncture site of filter placement;
	b. Patients with severe arrhythmia or myocardial infarction within 1 year;
	c. Chronic IVC thrombosis, severe stenosis, or malformation of the IVC or internal jugular vein;
	d. Pulmonary fibrosis and PE caused by the loss of embolus from the right heart cavity;
	e. Patients with massive PE, with life-threatening conditions;
	f. Patients with bacteremia, toxemia, or purulent embolism;
	g. Diameter of IVC greater than or equal to the maximum diameter of the backup filters;
	h. Severe liver and kidney dysfunction (ALT and AST more than 3 times the upper limit of normal value; Cr >225 μmol/L);
	i. Patients with blood pressure higher than 180/110 mmHg that cannot be controlled by medication;
	j. INR >3.0 and an APTT more than 5 times the upper limit of normal value in patients with severe coagulopathy;
	k. Patients allergic to the components of the contrast agent or filter system;
	l. Patients with active cancer or life expectancy <6 months;
	m. Patients with mental disease, psychological disorders that cannot be properly expressed, or alcoholism and drug dependence (e.g., drug addiction);
	n. Participants who have participated in clinical trials of other drugs or medical devices within 3 months prior to screening;
	o. Pregnant or lactating women, recent birth, or inability to take viable contraceptive measures during the trial;
	p. Other conditions that the investigator deemed inappropriate for participation in the clinical trial

IVC, inferior vena cava; PE, pulmonary embolism; LEDVT, lower extremity deep vein thrombosis; PMT, percutaneous mechanical thrombectomy; ALT, alanine transaminase; AST, amino transferase; Cr, creatinine; INR, international normalized ratio; APTT, activated partial thromboplastin time.

https://dx.doi.org/10.21037/qims-24-879